



### Editor

Tracy Crooks

Reckitt Benckiser Healthcare International Ltd  
email: [tracy.crooks@reckittbenckiser.com](mailto:tracy.crooks@reckittbenckiser.com)

### Advisory Panel

Elliot Brown

Managing Director, Elliot Brown Consulting Ltd

David Cousins

Head of Safe Medication Practice, National Patient Safety Agency

Alison Ewing

Clinical Director of Pharmacy, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Graeme Ladds

Director, PharSafer Associates Ltd.

Sunayana Shah

Scientific & Medical Affairs Manager at the Proprietary Association of Great Britain (PAGB)

### Publisher

Joe Ridge

### Design & Production

Sarah Beale

### Subscriptions

Jill Monk

email: [subs@euromedcommunications.com](mailto:subs@euromedcommunications.com)

Published by Euromed Communications Ltd  
Passfield Business Centre, Passfield, Liphook,  
Hampshire GU30 7SB, UK  
Tel: +44 (0)1428 752222  
Fax: +44 (0)1428 752223

email: [info@euromedcommunications.com](mailto:info@euromedcommunications.com)  
[www.euromedcommunications.com](http://www.euromedcommunications.com)

Euromed Communications Ltd also publish  
Clinical Research Manual; Paediatric Clinical  
Research Manual, Medical Devices Manual and  
Compendium of Quality of Life Instruments

Copyright: No part of this journal may be reproduced without written permission from the Publishers. The comments of the contributors are their own and are not necessarily endorsed by the Publisher, Editor or Advisory Panel. Accordingly the Publisher, Editor or Advisory Panel accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement. The Editor's decision is final and no correspondence will be entered into. The utmost care has been taken to ensure accuracy of detail, but the publishers cannot accept responsibility for errors or omissions.

© 2012 Euromed Communications Ltd

ISSN 1752-6752

# Contents

August 2012 • Volume 6 Number 3

## 3 Editorial comment

Tracy Crooks

## 4 The new pharmacovigilance legislation

Questions & Answers provided by the EMA relating to what is undoubtedly the biggest change to the EU regulation of medicines for over 17 years.

## 10 Lost in translation?

When patient information crosses borders

The Danish authors look at the possible misunderstandings and safety risks of translating PILs into various languages  
*Inger Askehave and Karen Korning Zethsen*

## 14 The use of safety biomarkers for risk assessment of investigational drugs entering first time in human studies

Sensitive biomarkers are increasingly important in identifying early toxicity and so improving the selection of drugs with therapeutic potential.

*Nicholas APS Buss*

## 17 The role of the contract QPPV

The challenges faced by the contract QPPV and the MAH when overseeing vigilance activities

*Deidre McCarthy*

## 20 UK Inspection findings for 2011/2012

Recently published figures show a continuing improvement in compliance, quality data and product safety concerns